MetaCap

Arcutis Biotherapeutics (ARQT) vs Disc Medicine (IRON)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Arcutis Biotherapeutics (ARQT) has outperformed Disc Medicine (IRON) over the past year, losing 10.6% versus a loss of 18.9%. Over five years, ARQT leads with a +58.1% price change compared with -14.2% for IRON. Disc Medicine is the larger company by market cap ($3.42 billion vs $3.33 billion), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ARQT-10.61%IRON-18.86%
+18%-12%-43%
Nov 21, 20251 yearNov 20, 2026
ARQT+44.91%IRON-22.46%
+85%-7%-98%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ARQT versus IRON key metrics
MetricARQTIRON
Share price$26.36$75.14
Market cap$3.33B$3.42B
1-day change-2.98%-1.27%
YTD return-9.23%-5.38%
1-year return-10.61%-18.86%
5-year return+58.13%-14.22%
P/E ratio (TTM)119.82—
Forward P/E24.09—
EPS (TTM)$0.22$-6.34
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$376.07M—
Revenue growth (YoY)+91.34%—
Net income (latest FY)$-16.14M$-212.18M
Gross margin90.24%—
Operating margin-3.25%—
Net margin-4.29%—
52-week high$34.80$99.50
52-week low$19.30$40.00
Distance from 52-week high-24.25%-24.48%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+53.19%+69.94%
Average volume2.58M951.56K
Shares outstanding126.46M45.54M
Employees354173
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Arcutis Biotherapeutics

ARQT stock →

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.

Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees

About Disc Medicine

IRON stock →

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.

Health Care · Biotechnology: Pharmaceutical Preparations · 173 employees

ARQT vs IRON FAQ

Which is bigger, Arcutis Biotherapeutics or Disc Medicine?

Disc Medicine (IRON) is larger, with a market capitalization of $3.42B compared with $3.33B for Arcutis Biotherapeutics (ARQT).

Which stock has performed better over the past year, ARQT or IRON?

ARQT returned -10.61% over the past 12 months, compared with -18.86% for IRON (price return, excluding dividends). Past performance does not predict future results.

Are Arcutis Biotherapeutics and Disc Medicine in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons